Ofev (nintedanib capsules - Boehringer Ingelheim) — Cigna
Interstitial Lung Diseases, Chronic Fibrosing with a Progressive Phenotype
Initial criteria
- Age ≥ 18 years
- Forced vital capacity ≥ 40% of predicted value
- According to the prescriber, the patient has fibrosing lung disease impacting more than 10% of lung volume on high-resolution computed tomography
Approval duration
1 year